Strategic AI/ML Interventions Aligned to the 2026 Rare Disease Strategic Agenda from FDA Rare Disease Innovation Hub.

2026 is redefining obesity treatment—moving from weight loss alone to oral therapies, muscle preservation, and long-term metabolic health.

2026 will be a pivotal year for drug development—read our latest white paper to explore the late-stage clinical trial readouts set to reshape medicine and markets.

China is no longer just in the pharma race — it’s helping define where global innovation comes from.

2026 marks biotech’s shift to precision cures—removing disease proteins, retraining biology, and targeting delivery to unlock safer, more durable therapies and long-term clinical leadership.

2025 emerged as a pivotal year for rare-disease dealmaking, driven by advanced biologics, strategic licensing, and strong unmet medical needs.

Big Pharma M&As are driven by premium platform technologies, neurology, oncology and obesity bets and near-term readouts that will validate the deals.

Oncology remains the undisputed leader in global dealmaking for 2025, fueled by relentless demand for differentiated therapies and next-generation modalities

Innoplexus’ CTP model forecasts the outcome of clinical studies and may serve as an early indicator for future stock movements.

Emergence of chimeric antigen receptor-t (CAR-T) cell therapies for cancer treatment

Gene therapy promises to hold the cure to a number of diseases which, until now, have been considered incurable. Read our recent whitepaper